Generic name: PIBRENTASVIR 40mg, GLECAPREVIR 100mg
Dosage form: tablet, film coated
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Testing Prior to the Initiation of Therapy
Test all patients for evidence of current or prior HBV infection by measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) before initiating HCV treatment with MAVYRET [see Warnings and Precautions (5.1)].
Recommended Dosage in Adults
The recommended oral dosage of MAVYRET is three tablets (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg) taken once daily with food [see Clinical Pharmacology (12.3)].
Tables 1 and 2 provide the recommended MAVYRET treatment duration based on the patient population in HCV mono-infected and HCV/HIV-1 co-infected patients with compensated liver disease (with or without cirrhosis) and with or without renal impairment including patients receiving dialysis.
|No Cirrhosis||Compensated Cirrhosis
|1, 2, 3, 4, 5, or 6||8 weeks||12 weeks|
Treated With a
|1||An NS5A inhibitor1 without prior treatment with an NS3/4A protease inhibitor||16 weeks||16 weeks|
|An NS3/4A PI2 without prior treatment with an NS5A inhibitor||12 weeks||12 weeks|
|1, 2, 4, 5, or 6||PRS3||8 weeks||12 weeks|
|3||PRS3||16 weeks||16 weeks|
More about Mavyret (glecaprevir / pibrentasvir)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 8 Reviews – Add your own review/rating
- Drug class: antiviral combinations